This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.
Even past the second wave, as vaccines become available, healthcare systems will not return rapidly to pre-pandemic capacities, let alone deliver more than that capacity. Pharmaceuticalcompanies cannot address this challenge alone. The conclusion is that backlog clearance will extend into 2021.
Pharmaceuticalcompanies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Innate Pharma has also partnered with Takeda to develop an antibody drug conjugate (ADC).
The world’s biggest pharmaceuticalcompany Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. “Companies used to be universally protected by patents but there is a pathway to approval opening up for biosimilar legislation. .
New responsibilities, new arenas The potential for in-hospital manufacturing is further developing due to the new responsibilities assigned to hospital pharmacy staff, such as centralised preparation of chemotherapies and drugs for clinical trials, extemporaneous production of radiopharmaceuticals and cellular therapies, to name but a few.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content